Bernard Verrier
Overview
Explore the profile of Bernard Verrier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
2609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ayad C, Porter D, Lambert E, Libeau P, Coiffier C, Ginet V, et al.
Vaccine
. 2025 Mar;
53:126957.
PMID: 40031086
mRNA vaccines are poised to revolutionize disease prevention, following the approval of their administration to humans against SARS-CoV-2. Although they have been extensively studied for human applications, their potential in...
2.
Durmaz K, Misbach M, Danoy A, Salvi J, Bloch E, Bourrelly S, et al.
J Hazard Mater
. 2024 Apr;
470:134190.
PMID: 38593659
Organophosphorus compounds (OPs), such as VX, pose a significant threat due to their neurotoxic and hazardous properties. Skin decontamination is essential to avoid irreversible effects. Fuller's earth (FE), a phyllosilicate...
3.
Resseguier J, Nguyen-Chi M, Wohlmann J, Rigaudeau D, Salinas I, Oehlers S, et al.
Sci Adv
. 2023 Nov;
9(44):eadj0101.
PMID: 37910624
The constant exposure of the fish branchial cavity to aquatic pathogens causes local mucosal immune responses to be extremely important for their survival. Here, we used a marker for T...
4.
Trimaille T, Verrier B
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896241
Historically used for the delivery of hydrophobic drugs through core encapsulation, amphiphilic copolymer micelles have also more recently appeared as potent nano-systems to deliver protein and peptide therapeutics. In addition...
5.
Lamrayah M, Phelip C, Rovera R, Coiffier C, Lazhar N, Bartolomei F, et al.
Molecules
. 2023 Jun;
28(12).
PMID: 37375333
Vaccine technology is still facing challenges regarding some infectious diseases, which can be addressed by innovative drug delivery systems. In particular, nanoparticle-based vaccines combined with new types of adjuvants are...
6.
Yavuz A, Coiffier C, Garapon C, Gurcan S, Monge C, Exposito J, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986871
mRNA-based vaccines have made a leap forward since the SARS-CoV-2 pandemic and are currently used to develop anti-infectious therapies. If the selection of a delivery system and an optimized mRNA...
7.
Ayari-Riabi S, Ben Khalaf N, Bouhaouala-Zahar B, Verrier B, Trimaille T, Benlasfar Z, et al.
Molecules
. 2022 Dec;
27(24).
PMID: 36557812
Leishmaniasis is the 3rd most challenging vector-borne disease after malaria and lymphatic filariasis. Currently, no vaccine candidate is approved or marketed against leishmaniasis due to difficulties in eliciting broad immune...
8.
Lamrayah M, Charriaud F, Desmares M, Coiffier C, Megy S, Colomb E, et al.
Antiviral Res
. 2022 Dec;
209:105483.
PMID: 36496142
Hepatitis B virus remains a major medical burden with more than 250 million chronically infected patients worldwide and 900,000 deaths each year, due to the disease progression towards severe complications...
9.
Monge C, Ayad C, Paris A, Rovera R, Colomb E, Verrier B
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362224
Among mucosal administration routes for vaccines, the sublingual route has been proven capable of inducing a potent systemic and mucosal immune response. However, the absence of a simple and compliant...
10.
Desmares M, Delphin M, Chardes B, Pons C, Riedinger J, Michelet M, et al.
Antiviral Res
. 2022 Aug;
206:105386.
PMID: 35963549
Objectives: Pegylated-interferon-alpha (Peg-IFNα), an injectable innate immune protein, is still used to treat chronically HBV-infected patients, despite its poor tolerability. Peg-IFNα has the advantage over nucleos(t)ide analogues (NAs) to be...